Rory Shallis, MD
Assistant Professor AdjunctCards
Contact Info
About
Titles
Assistant Professor Adjunct
Biography
Dr. Shallis received his MD from Rutgers-Robert Wood Johnson Medical School, completed his residency training at Brown University-Rhode Island Hospital and fellowship training at Yale-New Haven Hospital.
He is focused on the care and research of patients with myeloid malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He also participated in the K12 Calabresi Immuno-Oncology Training Program and currently participates as an investigator in several clinical trials aimed at improving the outcomes of patients with AML and MDS.
Dr. Shallis also maintains research interest in epidemiological, outcomes and effectiveness research as it pertains to the hematologic malignancies with a goal of identifying barriers to effective care and ultimately strategies to improve the outcomes of patients with these malignant diseases. Dr. Shallis conducts research with the Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center at Yale University.
Dr. Shallis has presented his research at multiple regional, national and international meetings and is a member of the National Comprehensive Cancer Network (NCCN) clinical guidelines for MDS and AML panels. He is an author on more than 75 peer-reviewed publications and book chapters, most of which as first author and has served as an ad hoc reviewer for many journals including Leukemia, Haematologica, Blood Advances, Leukemia Research, Leukemia & Lymphoma, Acta Haematologica, Hematology, Therapeutic Advances in Hematology, Expert Review of Hematology, BMC Hematology, eJHaem and Future Oncology among others.
Appointments
Medical Oncology and Hematology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
- Developmental Therapeutics
- Leukemia & Lymphoma Program
- Medical Oncology and Hematology
Education & Training
- Fellowship
- Yale - New Haven Hospital (2020)
- Internship
- Brown University - Rhode Island Hospital (2017)
- Residency
- Brown University - Rhode Island Hospital (2017)
- MD
- Rutgers University - Robert Wood Johnson Medical School (2014)
- BA
- Rutgers College, Cell Biology & Neuroscience Psychology (2010)
Research
Overview
Medical Research Interests
ORCID
0000-0002-8542-2944
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Amer Zeidan, MBBS
Jan Philipp Bewersdorf, MD, FACP
Nikolai Podoltsev, MD, PhD
Maximilian Stahl, MD
Rong Wang, PhD
Xiaomei Ma, PhD
Myelodysplastic Syndromes
Myeloproliferative Disorders
Leukemia
Myelodysplastic-Myeloproliferative Diseases
Publications
2025
Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab
Bewersdorf J, Hasle V, Shallis R, Thompson E, de Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox B, Zeidan A. Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. Therapeutic Advances In Hematology 2025, 16: 20406207251347344. PMID: 40546817, PMCID: PMC12182606, DOI: 10.1177/20406207251347344.Peer-Reviewed Original ResearchAltmetricConceptsAcute myeloid leukemiaImmune checkpoint inhibitorsMDS patientsCheckpoint inhibitorsSF mutationsMutation statusAnti-PD-L1 antibody durvalumabSusceptible to immune checkpoint inhibitorsWild-type acute myeloid leukemiaDiagnosed AMLBone marrow aspirate samplesAssociated with adverse outcomesMedian overall survivalWild-type patientsGeneration of neoantigensPost hoc analysisPD-L1Overall survivalPrimary endpointPreclinical dataMyeloid leukemiaAspirate samplesOlder patientsGene expression profilesAdverse outcomesShould we treat TP53-mutated high-risk myeloid neoplasms in older patients?
Badar T, E.l. Kettani M, Shah K, Jamy O, Shallis R, Diebold K, Coltoff A, Goldberg A, Patel A, Bewersdorf J, Foucar C, Abaza Y, Palmisiano N, DuVall A, Kota V, Zeidan A, Atallah E, Litzow M. Should we treat TP53-mutated high-risk myeloid neoplasms in older patients? Journal Of Clinical Oncology 2025, 43: 6538-6538. DOI: 10.1200/jco.2025.43.16_suppl.6538.Peer-Reviewed Original ResearchConceptsMedian overall survivalHigh-risk myeloid neoplasmsAllo-HCTDuration of responseTP53-MTHypomethylating agentsVariant allele frequencyOlder ptsMyeloid neoplasmsECOG-PSHR-MDSEastern Cooperative Oncology Group performance statusMedian duration of responseTP53 variant allele frequencyAllogeneic stem cell transplantationECOG-PS 0De novo AMLLong-term remissionStem cell transplantationLow-intensity therapyMulticenter observational studyProportion of ptsDisease-directed therapyMulti-center studyMPN-BPHeterogeneity in outcomes of TP53‐mutated myeloproliferative neoplasms based on disease phenotype and mutational status
Badar T, Foran J, Bewersdorf J, Wang Y, Coltoff A, Kettani M, Shah K, Oliva F, Lin C, Jamy O, Diebold K, Shallis R, Siddon A, Katkov D, Schoen A, Khan I, Foucar C, Atallah E, Goldberg A, Patel A. Heterogeneity in outcomes of TP53‐mutated myeloproliferative neoplasms based on disease phenotype and mutational status. British Journal Of Haematology 2025 PMID: 40400334, DOI: 10.1111/bjh.20187.Peer-Reviewed Original ResearchAltmetricAssessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy
Shaw R, Yoon J, Johnston H, Davidson M, Siddon A, Shallis R, Chen E, Burkart M, Oh T, Iyer S, Madarang E, Muthiah C, Kassner J, Rampal R, Murthy S, Bradley T, Abaza Y, Garcia J, Gupta V, Pettit K, Odenike O, Patel A. Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy. Blood Advances 2025, 9: 2453-2457. PMID: 39969200, PMCID: PMC12144506, DOI: 10.1182/bloodadvances.2024015712.Peer-Reviewed Original ResearchAltmetricConceptsResponse and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms
Goldberg L, Yoon J, Johnston H, Davidson M, Siddon A, Shallis R, Chen E, Burkart M, Oh T, Iyer S, Madarang E, Muthiah C, Kassner J, Rampal R, Murthy S, Bradley T, Abaza Y, Garcia J, Gupta V, Pettit K, Odenike O, Cursio J, Patel A. Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms. Blood Neoplasia 2025, 2: 100089. DOI: 10.1016/j.bneo.2025.100089.Peer-Reviewed Original ResearchAltmetricFeasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Shallis R, Weiss J, Winer E, Badar T, Swaroop A, Doukas P, Geramita E, Le H, Agarwal S, Merl M, Abaza Y, Im A, Litzow M, Podoltsev N. Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia & Lymphoma 2025, ahead-of-print: 1-5. PMID: 40294060, DOI: 10.1080/10428194.2025.2496339.Peer-Reviewed Original ResearchCitationsAltmetricCARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX: A MULTICENTER STUDY
Filimon S, Ghamari A, Vakilpour A, Patel R, Achar R, Akhter N, Shallis R, DeCara J, Anazco F, Altman J, Smith A, Matthews A, Lai C, Brunner A, Farina K, Gilman H, Neilan T, Upadhyay D, Patel A, Tremblay D, Scherrer-Crosbie M. CARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX: A MULTICENTER STUDY. Journal Of The American College Of Cardiology 2025, 85: 2865. DOI: 10.1016/s0735-1097(25)03349-2.Peer-Reviewed Original ResearchReal‐World Outcomes of Relapsed/Refractory Core‐Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study
Rojek A, McCormick B, Cwykiel J, Odetola O, Abaza Y, Nai N, Foucar C, Achar R, Shallis R, Bradshaw D, Standridge M, Kota V, Murthy S, Badar T, Patel A. Real‐World Outcomes of Relapsed/Refractory Core‐Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study. American Journal Of Hematology 2025, 100: 1082-1085. PMID: 40062542, PMCID: PMC12068978, DOI: 10.1002/ajh.27664.Peer-Reviewed Original ResearchAltmetricConceptsNCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.
Greenberg P, Stone R, Abaza Y, Al-Kali A, Anand S, Ball B, Bennett J, Borate U, Brunner A, Chai-Ho W, Curtin P, DeZern A, Gaensler K, Gahvari Z, Garcia-Manero G, Griffiths E, Haque T, Jacoby M, Jonas B, Keel S, Khanal R, Kishtagari A, Madanat Y, Maness L, McCurdy S, McMahon C, Odenike O, Osman A, Reddy V, Sallman D, Sayar H, Shallis R, Singh A, Tanaka T, Thota S, Kovach E, Nguyen J, Hochstetler C. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025. Journal Of The National Comprehensive Cancer Network 2025, 23: 66-75. PMID: 40073835, DOI: 10.6004/jnccn.2025.0013.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNCCN Guidelines InsightsHigher-risk MDSComprehensive care of patientsPrognostic significanceNCCN GuidelinesClinical evidenceCare of patientsTreatment recommendationsMultidisciplinary panelNovel therapeuticsTherapeutic agentsNCCNLowered riskComprehensive careTreatmentBiological factorsPatientsReal-World Analysis of Strategies to Prevent Thrombosis and Bleeding in Adults with ALL Treated with Asparaginase
Mort J, Brighton D, Mautner B, Pierce E, Ghamsari F, Allen C, D’souza D, Patel I, Lawson J, Jackson C, Abernathy K, Yelvington B, Miller R, Dholaria B, Wolfe H, Infield J, Locke S, Shallis R, Duong V, Reed D, Walsh K, LeBlanc T, Keng M, Horton B, Chaer F. Real-World Analysis of Strategies to Prevent Thrombosis and Bleeding in Adults with ALL Treated with Asparaginase. Blood Vessels Thrombosis & Hemostasis 2025, 100065. DOI: 10.1016/j.bvth.2025.100065.Peer-Reviewed Original ResearchConceptsAcute lymphoblastic leukemiaOdds of thrombosisProphylactic anticoagulationPEG-ASPIncreased rate of thrombosisPrognosis of adult patientsAcute lymphoblastic leukemia therapyPediatric-inspired regimensPeripherally inserted central cathetersRandomized prospective studyRate of thrombosisOdds of bleedingAssociated thrombosisPegylated asparaginaseLymphoblastic leukemiaThrombotic riskRetrospective studyThrombotic eventsAdult patientsReal-world analysisProspective studyCentral cathetersBleedingMultivariate analysisAnticoagulation
Academic Achievements & Community Involvement
Activities
activity National Comprehensive Cancer Network (NCCN) - Myelodysplastic Syndromes Guideline Panel
12/01/2020 - PresentCommitteesMemberactivity Older Adult AML Working Group - National Cancer Institute (NCI) Myeloid Precision Medicine Initiative
09/01/2020 - PresentPeer Review Groups and Grant Study SectionsMemberactivity ECOG-ACRIN Leukemia Committee
07/23/2020 - PresentCommitteesMemberactivity American Society of Hematology (ASH)
07/03/2017 - PresentProfessional OrganizationsMemberactivity American Society of Clinical Oncology (ASCO)
07/03/2017 - PresentProfessional OrganizationsMember
Honors
honor Top Overall Abstract
06/08/2020Regional AwardMyeloid Malignancies SymposiumDetailsUnited Stateshonor Hematology/Oncology Fellowship Program Research Award
06/01/2019Yale School of Medicine AwardYale Cancer CenterDetailsUnited States
News
News
- December 13, 2024Source: OncLive
How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD
- November 26, 2024
Yale Cancer Center to Highlight Breakthroughs in Blood Cancers and Disorders at World’s Largest Hematology Meeting
- May 01, 2024
Yale Department of Internal Medicine Faculty Promotions and Appointments (May 2024)
- March 25, 2024
Yale’s Post ASH Review